Mekinist (trametinib tablets and oral solution – Novartis) — Cigna

Initial criteria

• Patient has unresectable, advanced (including Stage III or Stage IV disease), or metastatic melanoma; AND
• Patient meets ONE of the following (i or ii): i. Patient has BRAF mutation-positive disease; OR ii. Patient has BRAF fusion-positive disease.

Approval duration

1 year